REATA PHARMACEUTICALS INC-A (RETA) Stock News
NASDAQ:RETA - Nasdaq - US75615P1030 - Common Stock - Currency: USD
RETA Latest News, Press Relases and Analysis
Kirby McInerney LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of Reata Pharmaceuticals, Inc. Common Stock
/PRNewswire/ -- TO: All persons and entities who, during the period between November 14, 2016 through December 8, 2021 inclusive, purchased or otherwise...
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
An Oversold Gold Miner With Strong Fundamentals--Its Relative Strength Index Is Below 20, And Its Piotroski F-Score Is 8
Paying Attention To Gold Miners On Zero Hedge on Monday, contributing editor “Quoth The Raven” suggested “paying urgent attention to gold miners”:
Reta shareholders clear buyout deal with Biogen (NASDAQ:RETA)
Reata Pharmaceuticals (RETA) said that its shareholders approved its previously disclosed acquisition by Biogen (BIIB) at a special meeting on Thursday. Read more here.
Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.
Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?
Buying a biotech is a good move, but it might not be enough to entice investors.
Mentions: BIIB
7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth
Finding the best pharma stocks to buy takes a little effort, but it will pay of with these seven long-term winners.
With an Acquisition on the Way, Is Biogen Stock a Buy?
Can the biotech finally get back in the good graces of investors?
Mentions: BIIB
The 7 Most Promising Momentum Stocks to Own Now
These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility.
The 3 Most Promising Pharma Stocks to Own Now
A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride.
Sanofi was mystery bidder in Reata Pharma bidding war - report
Sanofi (SNY) was the other buyer in the recent bidding war for Reata Pharmaceuticals (RETA), narrowly losing out to Biogen's $7.3 billion offer
Sanofi Was Mystery Bidder That Lost Reata to Biogen
Biogen Inc. narrowly beat out Sanofi SA to clinch its $7.3 billion acquisition of Reata Pharmaceuticals, according to people familiar with the matter.
Mentions: BIIB
Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points
Investors looking to give their portfolio a boost should consider one of these leading biotech names, which are undervalued right now.